Vesicants |
Amsacrine |
Dactinomycin |
Daunorubicin |
Doxorubicin |
Epirubicin |
Idarubicin |
Lurbinectedin |
Mechlorethamine |
Mitomycin |
Trabectedin |
Vinblastine |
Vincristine and liposomal vincristine |
Vindesine |
Vinorelbine |
Irritants |
Ado-trastuzumab emtansine* |
Bendamustine¶ |
Bleomycin |
Bortezomib |
Busulfan |
Carboplatin |
Carmustine |
CisplatinΔ |
Cladribine |
Cyclophosphamide |
Cytarabine |
DacarbazineΔ |
Docetaxel |
Enfortumab vedotin |
Etoposide |
Fluorouracil/floxuridine |
Gemcitabine |
Ifosfamide |
Irinotecan¶ |
Ixabepilone |
Liposomal daunorubicin¶ |
Liposomal doxorubicin¶ |
Melphalan¶ |
Mitoxantrone¶ |
Oxaliplatin¶ |
Paclitaxel¶ |
Paclitaxel, nanoparticle albumin bound (nabpaclitaxel) |
Streptozocin |
Teniposide |
Topotecan |
* A single case of skin necrosis after ado-trastuzumab emtansine extravasation has been reported.[1]
¶ Irritants that may cause soft tissue injury when extravasated.
Δ May have vesicant properties depending on the concentration of volume of drug extravasated. As an example, extravasation of a large volume (>20 mL) of concentrated cisplatin (>0.5 mg/mL) may produce tissue necrosis.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟